Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index; 26 of the 48 sources its claims cite were checked for support.
Abstract
Candida albicans is the leading fungal pathogen of humans, causing life-threatening disease in immunocompromised individuals. Treatment of candidiasis is hampered by the limited number of antifungal drugs whose efficacy is compromised by host toxicity, fungistatic activity, and the emergence of drug resistance. We previously established that the molecular chaperone Hsp90, which regulates the form and function of diverse client proteins, potentiates resistance to the azoles in C. albicans and in the model yeast Saccharomyces cerevisiae. Genetic studies in S. cerevisiae revealed that Hsp90's role in azole resistance is to enable crucial cellular responses to the membrane stress exerted by azoles via the client protein calcineurin. Here, we demonstrate that Hsp90 governs cellular circuitry required for resistance to the only new class of antifungals to reach the clinic in decades, the echinocandins, which inhibit biosynthesis of a critical component of the fungal cell wall. Pharmacological or genetic impairment of Hsp90 function reduced tolerance of C. albicans laboratory strains and resistance of clinical isolates to the echinocandins and created a fungicidal combination. Compromising calcineurin function phenocopied compromising Hsp90 function. We established that calcineurin is an Hsp90 client protein in C. albicans: reciprocal co-immunoprecipitation validated physical interaction; Hsp90 inhibition blocked calcineurin activation; and calcineurin levels were depleted upon genetic reduction of Hsp90. The downstream effector of calcineurin, Crz1, played a partial role in mediating calcineurin-dependent stress responses activated by echinocandins. Hsp90's role in echinocandin resistance has therapeutic potential given that genetic compromise of C. albicans HSP90 expression enhanced the efficacy of an echinocandin in a murine model of disseminated candidiasis. Our results identify the first Hsp90 client protein in C. albicans, establish an entirely new role for Hsp90 in mediating resistance to echinocandins, and demonstrate that targeting Hsp90 provides a promising therapeutic strategy for the treatment of life-threatening fungal disease.
Overview
CoChat Summary
## TL;DR
Hsp90 is required for *Candida albicans* tolerance to echinocandins, and this effect depends largely on calcineurin. Genetic or pharmacological impairment of Hsp90 or calcineurin made micafungin more effective in vitro and in a murine disseminated infection model.
## Key findings
- In antifungal susceptibility and spotting assays, inhibiting Hsp90 with geldanamycin (GdA) or radicicol (RAD) “dramatically enhanced” sensitivity to micafungin (MF) in two strains, and comparable effects were seen with caspofungin (CS).
- Compromising Hsp90 function made the tetO-HSP90/hsp90Δ strain hypersensitive to MF even without tetracycline, and restoring a wild-type HSP90 allele complemented both the reduced growth rate and MF hypersensitivity.
- Inhibiting calcineurin with cyclosporin A (CsA) or FK506 abolished MF tolerance; deleting CNA1 or CNB1 also abrogated MF tolerance, while CRZ1 deletion caused only a partial loss of MF tolerance.
- In the murine model, mice infected with the tetO-HSP90/hsp90Δ strain had significantly reduced kidney fungal burden than mice infected with wild-type HSP90 strain (P<0.05), and MF further reduced fungal burden in the tetO-HSP90/hsp90Δ group (P<0.001).
## Methods
- The study combined pharmacological inhibition (GdA, RAD, CsA, FK506) and genetic perturbation (HSP90, CNA1, CNB1, CRZ1 mutants; tetO-HSP90/hsp90Δ; MAL2p-HSP90/hsp90Δ) in *C. albicans* and *S. cerevisiae*.
- Antifungal tolerance was measured using modified broth microdilution MIC assays, checkerboard synergy assays, and spotting assays on liquid and solid media with MF and CS.
- Mechanistic tests included β-galactosidase reporter assays for calcineurin activation, co-immunoprecipitation of tagged Hsp90 and Cna1, immunoblotting for protein levels, and a tail-vein murine disseminated candidiasis model with kidney CFU readout.
## Limitations
- The paper explicitly notes that the basis for the different responses with micafungin and caspofungin on solid medium is unclear, and the response with anidulafungin “remains to be determined.”
- The authors state that synergy between Hsp90/calcineurin inhibitors and MF was not observed for all echinocandin-resistant clinical isolates tested; of 14 FKS1 mutants, synergy was observed for 8.
- Evidence on cidality was limited by MF-induced clumping, which made CFU counts inaccurate in the echinocandin killing assay; this is stated in the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
19 Valid · 3 Not valid · 19 Not checked · 75 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“This antibody also demonstrated synergy with the echinocandin caspofungin in a murine model [53].”
§ Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin > Discussion
What the sources say
- Supportedcites [53] S Hodgetts, 2008, Efungumab and caspofungin: pre-clinical data supporting synergy., J Antimicrob Chemother source
The Introduction identifies efungumab as a human recombinant antibody fragment against Hsp90. The Abstract reports a statistically significant improvement with efungumab plus caspofungin in mice infected with fluconazole-resistant C. albicans, supporting the claimed synergy in a murine model. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Current Hsp90 inhibitors that are well-tolerated in humans as anti-cancer agents exhibit toxicity in the mouse model in the context of an acute fungal infection [22].”
§ Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin > Discussion
What the sources say
- Supportedcites [22] LE Cowen, 2009, Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease., Proc Natl Acad Sci U S A source
The Discussion states that Hsp90 inhibitors in clinical development as anticancer agents are well tolerated in humans. It also reports significant toxicity with two structurally unrelated Hsp90 inhibitors in a mouse model of acute disseminated C. albicans infection. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, in an invertebrate model of fungal pathogenesis, these pharmacological inhibitors of Hsp90 function enhance the efficacy of the two most widely deployed classes of antifungal drugs, azoles and echinocandins, against the two leading fungal pathogens of humans, Candida albicans and Aspergillus fumigatus [22].”
§ Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin > Discussion
What the sources say
- Supportedcites [22] LE Cowen, 2009, Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease., Proc Natl Acad Sci U S A source
The Abstract describes improved efficacy of fluconazole plus Hsp90 inhibitors against C. albicans in Galleria mellonella larvae, and improved larval survival with an Hsp90 inhibitor plus caspofungin against A. fumigatus. The Discussion likewise reports that combination therapy rescued lethal infections with both fungi in this invertebrate host. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This recombinant antibody had therapeutic benefits in a clinical trial in combination with amphotericin B, which targets ergosterol [52].”
§ Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin > Discussion
What the sources say
- Supportedcites [52] J Pachl, 2006, A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis., Clin Infect Dis source
The Abstract identifies Mycograb as a recombinant antibody against fungal heat shock protein 90 and reports better treatment responses when it was combined with lipid-associated amphotericin B than when amphotericin B was given with placebo. The Discussion likewise describes improved clinical and mycological resolution. These passages support the claimed therapeutic benefit in the clinical trial. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with previous findings [23], we confirmed that Hsp90 and calcineurin physically interact in S. cerevisiae (Figure 9A), as they do in C. albicans (Figure 4).”
§ Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin > Results > Divergence of Hsp90 and calcineurin's role in echinocandin tolerance in S. cerevisiae
What the sources say
- Supportedcites [23] J Imai, 2000, Role of HSP90 in salt stress tolerance via stabilization and regulation of calcineurin., Mol Cell Biol source
The Abstract reports that Hsc82, a yeast HSP90 homologue, coimmunoprecipitated with the calcineurin catalytic subunit Cna2 in Saccharomyces cerevisiae cells under normal conditions. The Discussion also says coimmunoprecipitation experiments revealed complexes of Cna2 with Hsp82 and Hsc82, supporting the attributed physical interaction. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
56 more claims · 1 with their cited sources checked
Create a free account to see all 116 claims and every source verdict.
- Probably not a substantial claim. 35
- It may state two separate claims as one. 27
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hsp90 enables crucial responses to drug-induced stress by orchestrating signaling through the protein phosphatase calcineurin and the protein kinase C (PKC) cell wall integrity signaling cascade [41], [46].”
From Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata (2012) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In C. albicans, key client proteins of Hsp90 include the Ca2+-calmodulin-activated protein phosphatase calcineurin, and multiple members of the PKC-MAPK cell wall integrity cascade (Pkc1, Bck1, Mkk2 and Mkc1)75–78.”
From Molecular mechanisms governing antifungal drug resistance (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, Hsp90 inhibition blocks the activation of calcineurin-dependent stress responses and PKC signalling, abrogating tolerance and resistance to the azole and echinocandin drugs76,78.”
From Molecular mechanisms governing antifungal drug resistance (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hsp90 depletion phenocopies the azole sensitivity of calcineurin and protein kinase C mutants96,101.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In Candida albicans and Aspergillus fumigatus, role of Hsp90 in echinocandin resistance has been well established [10].”
From Heat shock protein 90 localizes to the surface and augments virulence factors of Cryptococcus neoformans (2017) · cites this paper as [10]
Experimental — accuracy not yet measured
26 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“and are responsible for a broad spectrum of disease [1,2].”
BackgroundGlobal analysis of protein expression in yeast
Ghaemmaghami, S., Huh, W.-K., Bower, K., Howson, R. W., Belle, A., Dephoure, N., O'Shea, E. K., & Weissman, J. S. (2003) · Nature · doi:10.1038/nature02046 · Cited by 3,750 · cited 1×
“cerevisiae [36].”
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304 · cited 1×
“fumigatus is the principal causal agent of invasive aspergillosis with alarming mortality rates up to 90% that still remain at 40% with the best current treatment options [25,26].”
BackgroundPratt, W. B., & Toft, D. O. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800201 · Cited by 1,483 · cited 1×
“Hsp90 is an essential chaperone that regulates the form and function of many key signal transducers [17–19].”
BackgroundWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444 · cited 1×
“[32,33].”
Structure and mechanism of the Hsp90 molecular chaperone machinery
Pearl, L. H., & Prodromou, C. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142738 · Cited by 1,103 · cited 1×
“Hsp90 is an essential chaperone that regulates the form and function of many key signal transducers [17–19].”
BackgroundRoles of heat-shock proteins in innate and adaptive immunity.
Srivastava, P. (2002) · Nature reviews. Immunology · doi:10.1038/nri749 · Cited by 1,069 · cited 1×
“Consistent with this thinking, heat-shock proteins are immunodominant antigens for the recognition of many pathogens and play a central role in mediating both innate and adaptive immune responses [54,55].”
BackgroundRoe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004 · cited 1×
“[32,33].”
Zhao, R., Davey, M., Hsu, Y.-C., Kaplanek, P., Tong, A., Parsons, A. B., Krogan, N., Cagney, G., Mai, D., Greenblatt, J., et al. (2005) · Cell · doi:10.1016/j.cell.2004.12.024 · Cited by 819 · cited 2×
“cerevisiae [24], while to date not a single Hsp90 client protein has been characterized in C.”
BackgroundZaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., & Feudtner, C. (2005) · Clinical Infectious Diseases · doi:10.1086/496922 · Cited by 784 · cited 1×
“[2,3].”
Cited by
Candida albicans pathogenicity mechanisms
Mayer, F. L., Wilson, D., & Hube, B. (2013) · Virulence · doi:10.4161/viru.22913 · Cited by 1,848
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Self-citationThe Response to Heat Shock and Oxidative Stress in Saccharomyces cerevisiae
Morano, K. A., Grant, C. M., & Moye-Rowley, W. S. (2012) · Genetics · doi:10.1534/genetics.111.128033 · Cited by 652
Mechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
“Inhibition of Hsp90 reduces echinocandin resistance acquired by mutation in the drug target, and resistance that evolved in the human host (Singh et al. 2009; Singh-Babak et al. 2012).”
BackgroundInfluentialSelf-citationAntifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches
Roemer, T., & Krysan, D. J. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019703 · Cited by 593
“fumigatus, and that it is observed in an invertebrate model of candidiasis (Cowen et al. 2009; Singh et al. 2009; Shapiro et al. 2011).”
BackgroundRamage, G., Rajendran, R., Sherry, L., & Williams, C. (2012) · International Journal of Microbiology · doi:10.1155/2012/528521 · Cited by 583
“It physically interacts with the catalytic subunit of calcineurin, keeping it stable and poised for activation [180].”
BackgroundRegulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576
“Interestingly, FK506 activates Mpk1, which results in the induction of FKS1 expression.”
BackgroundResultInfluentialSelf-citationAntifungal drug resistance: evolution, mechanisms and impact
Revie, N. M., Iyer, K. R., Robbins, N., & Cowen, L. E. (2018) · Current Opinion in Microbiology · doi:10.1016/j.mib.2018.02.005 · Cited by 516
Self-citationMolecular Evolution of Antifungal Drug Resistance
Robbins, N., Caplan, T., & Cowen, L. E. (2017) · Annual Review of Microbiology · doi:10.1146/annurev-micro-030117-020345 · Cited by 441
Self-citationEchinocandin resistance in Candida.
Perlin, D. S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ791 · Cited by 374
“through its client protein calcineurin and effector Crz1 [32].”
LaFayette, S. L., Collins, C., Zaas, A. K., Schell, W. A., Betancourt-Quiroz, M., Gunatilaka, A. A. L., Perfect, J. R., & Cowen, L. E. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001069 · Cited by 329
Self-citationFitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B
Vincent, B. M., Lancaster, A. K., Scherz-Shouval, R., Whitesell, L., & Lindquist, S. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001692 · Cited by 322
“The erg3 erg11 strains were slightly less sensitive to calcineurin inhibitors, but showed a dramatically increased sensitivity to PKC inhibition.”
BackgroundInfluentialMechanisms of echinocandin antifungal drug resistance
Perlin, D. S. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12831 · Cited by 313
Molecular mechanisms governing antifungal drug resistance
Lee, Y., Robbins, N., & Cowen, L. E. (2023) · npj Antimicrobials and Resistance · doi:10.1038/s44259-023-00007-2 · Cited by 304
“Consequently, Hsp90 inhibition blocks the activation of calcineurin-dependent stress responses and PKC signalling, abrogating tolerance and resistance to the azole and echinocandin drugs 76,78 .”
Self-citationHsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms
Robbins, N., Uppuluri, P., Nett, J., Rajendran, R., Ramage, G., Lopez-Ribot, J. L., Andes, D., & Cowen, L. E. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002257 · Cited by 291
“A key mediator of Hsp90-dependent drug resistance is the protein phosphatase calcineurin [37,38,49].”
BackgroundInfluentialSelf-citationRosenberg, A., Ene, I. V., Bibi, M., Zakin, S., Segal, E. S., Ziv, N., Dahan, A. M., Colombo, A. L., Bennett, R. J., & Berman, J. (2018) · Nature Communications · doi:10.1038/s41467-018-04926-x · Cited by 270
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0002-2016 · Cited by 271
“Biochemical analysis con fi rmed that Hsp90 stabilizes the catalytic subunit of calcineurin and the terminal MAP kinase of the Pkc1 cell wall integrity pathway, Mkc1 (81, 105).”
BackgroundInfluentialSelf-citationRecent insights into Candida albicans biofilm resistance mechanisms
Mathé, L., & Van Dijck, P. (2013) · Current Genetics · doi:10.1007/s00294-013-0400-3 · Cited by 271
“lize it and prepare it for activation (Singh et al. 2009).”
InfluentialEvolution of heat‐shock protein expression underlying adaptive responses to environmental stress
Chen, B., Feder, M. E., & Kang, L. (2018) · Molecular Ecology · doi:10.1111/mec.14769 · Cited by 267
“…Leach et al., 2012; Shapiro et al., 2012), such as solute con- centration in aquatic environments (Rohner et al., 2013), drug resistance by pathogens (Cowen & Lindquist, 2005; Singh et al., 2009), as well as clinically relevant stress associated with human genetic diseases (Karras et al., 2017).”
BackgroundImmune defence to invasive fungal infections: A comprehensive review
Pathakumari, B., Liang, G., & Liu, W. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110550 · Cited by 264
Costa-de-Oliveira, S., & Rodrigues, A. G. (2020) · Microorganisms · doi:10.3390/microorganisms8020154 · Cited by 229
Fungal Cell Wall: Emerging Antifungals and Drug Resistance.
Lima, S. L., Colombo, A. L., & de Almeida Junior, J. N. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02573 · Cited by 223
Combinatorial strategies for combating invasive fungal infections
Spitzer, M., Robbins, N., & Wright, G. D. (2017) · Virulence · doi:10.1080/21505594.2016.1196300 · Cited by 218
“well-characterized Hsp90 client protein important for governing responses to antifungal-induced stress is the protein phosphatase calcineurin.(104) In pathogenic fungi, calcineurin regulates a myriad of physiological processes”
BackgroundSelf-citationElevated Cell Wall Chitin in Candida albicans Confers Echinocandin Resistance In Vivo
Lee, K. K., MacCallum, D. M., Jacobsen, M. D., Walker, L. A., Odds, F. C., Gow, N. A. R., & Munro, C. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00683-11 · Cited by 209
“A synergistic effect of micafungin with an Hsp90 and with a calcineurin inhibitor was observed in isolates harboring the F641S substitution in Fks1 (64).”
BackgroundGlobal Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata
Singh-Babak, S. D., Babak, T., Diezmann, S., Hill, J. A., Xie, J. L., Chen, Y.-L., Poutanen, S. M., Rennie, R. P., Heitman, J., & Cowen, L. E. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002718 · Cited by 205
Self-citationSchwarzmüller, T., Ma, B., Hiller, E., Istel, F., Tscherner, M., Brunke, S., Ames, L., Firon, A., Green, B., Cabral, V., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004211 · Cited by 191
“Furthermore, the Hsp90 heat shock protein has also been identified as a regulator of echinocandin tolerance acting through calcineurin signaling [36,39].”
BackgroundNew Horizons in Antifungal Therapy
Pianalto, K., & Alspaugh, J. (2016) · Journal of Fungi · doi:10.3390/jof2040026 · Cited by 190
“albicans in vitro and in an invertebrate model of candidiasis [153,154].”
BackgroundDermatophyte Resistance to Antifungal Drugs: Mechanisms and Prospectus
Martinez-Rossi, N. M., Bitencourt, T. A., Peres, N. T. A., Lang, E. A. S., Gomes, E. V., Quaresemin, N. R., Martins, M. P., Lopes, L., & Rossi, A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01108 · Cited by 183
“Some Hsps may be induced when cells undergo stressful conditions, such as the exposure to antifungal agents, and extremes of temperature or pH (Singh et al., 2009; Leach et al., 2012a; Tamayo et al., 2013; Tiwari et al., 2015).”
BackgroundPolke, M., Hube, B., & Jacobsen, I. D. (2015) · Advances in Applied Microbiology · doi:10.1016/bs.aambs.2014.12.002 · Cited by 184
Cross‐species discovery of syncretic drug combinations that potentiate the antifungal fluconazole
Spitzer, M., Griffiths, E., Blakely, K. M., Wildenhain, J., Ejim, L., Rossi, L., De Pascale, G., Curak, J., Brown, E., Tyers, M., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.31 · Cited by 183
“…compounds have successfully yielded combinations that are active against pathogenic fungi, including the combination of fluconazole with chemical inhibitors of Hsp90, calcineurin or ARF (Cowen et al, 2009; Singh et al, 2009; Epp et al, 2010) and the antibiotic polymyxin B (Zhai et al, 2010).”
Update on Antifungal Drug Resistance
Perlin, D. S., Shor, E., & Zhao, Y. (2015) · Current Clinical Microbiology Reports · doi:10.1007/s40588-015-0015-1 · Cited by 174
Systems-level antimicrobial drug and drug synergy discovery
Roemer, T., & Boone, C. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1205 · Cited by 159
Drug resistance in eukaryotic microorganisms
Fairlamb, A. H., Gow, N. A. R., Matthews, K. R., & Waters, A. P. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.92 · Cited by 156
Calcineurin-Crz1 Signaling in Lower Eukaryotes
Thewes, S. (2014) · Eukaryotic Cell · doi:10.1128/ec.00038-14 · Cited by 154
The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens
Arastehfar, A., Lass-Flörl, C., Garcia-Rubio, R., Daneshnia, F., Ilkit, M., Boekhout, T., Gabaldon, T., & Perlin, D. S. (2020) · Journal of Fungi · doi:10.3390/jof6030138 · Cited by 145
“glabrata isolates harboring mutati ns in FKS1 a d/or FKS2 ca be potenti t when used in combination with HSP90 inhibitors [36].”
BackgroundMethodLiu, S., Hou, Y., Chen, X., Gao, Y., Li, H., & Sun, S. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.12.009 · Cited by 164
Kim, S. H., Iyer, K. R., Pardeshi, L., Muñoz, J. F., Robbins, N., Cuomo, C. A., Wong, K. H., & Cowen, L. E. (2019) · mBio · doi:10.1128/mbio.02529-18 · Cited by 136
“fumigatus (8, 10, 14), we tested whether Hsp90 had an impact on azole resistance in C.”
BackgroundSelf-citationFungal persister cells: The basis for recalcitrant infections?
Wuyts, J., Van Dijck, P., & Holtappels, M. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007301 · Cited by 136
Heat Shock Protein 90 Is Required for Conidiation and Cell Wall Integrity in Aspergillus fumigatus
Lamoth, F., Juvvadi, P. R., Fortwendel, J. R., & Steinbach, W. J. (2012) · Eukaryotic Cell · doi:10.1128/ec.00032-12 · Cited by 136
“albicans and resulted in increased susceptibility to azoles and echinocandins in vitro and in a murine model of invasive candidiasis (8, 9, 31).”
Leach, M. D., Budge, S., Walker, L., Munro, C., Cowen, L. E., & Brown, A. J. P. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1003069 · Cited by 131
“To test this we determined the impact of Hsp90 depletion on Cek1 stability as Hsp90 client proteins are generally destabilised in the absence of Hsp90 [62,86,89].”
BackgroundSelf-citationHsp90 orchestrates stress response signaling governing fungal drug resistance
Cowen, L. E. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000471 · Cited by 130
“clinical isolates and creates a fungicidal combination”
Self-citationGarcía‐Effrón, G. (2020) · Journal of Fungi · doi:10.3390/jof6040262 · Cited by 143
“Oppositely, in Yarrowia lipolytica (heterotypic synonym: Candida lipolytica), there is only one FKS homologue (FKS1) that is essential for viability [62].”
BackgroundFan, F., Liu, Y., Liu, Y., Lv, R., Sun, W., Ding, W., Cai, Y., Li, W., Liu, X., & Qu, W. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106673 · Cited by 159
Dagley, M. J., Gentle, I. E., Beilharz, T. H., Pettolino, F. A., Djordjevic, J. T., Lo, T. L., Uwamahoro, N., Rupasinghe, T., Tull, D. L., McConville, M., et al. (2011) · Molecular Microbiology · doi:10.1111/j.1365-2958.2010.07503.x · Cited by 128
“Several signalling pathways act to ensure cell wall integrity, for example the PKC and HOG MAP kinase pathways (Paravicini et al., 1996; Eisman et al., 2006; Munro et al., 2007) and the Ca2+-calcineurin pathway (Wiederhold et al., 2005; Munro et al., 2007; Singh et al., 2009).”
BackgroundLysine Deacetylases Hda1 and Rpd3 Regulate Hsp90 Function thereby Governing Fungal Drug Resistance
Robbins, N., Leach, M. D., & Cowen, L. E. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.08.035 · Cited by 126
“The Hsp90 client protein calcineurin, a signal transducer and sensor of cellular stress, is a key mediator of Hsp90-dependent azole resistance in C. albicans and S. cerevisiae (Cowen and Lindquist, 2005; Singh et al., 2009).”
BackgroundMethodInfluentialSelf-citationThe Future of Antifungal Drug Therapy: Novel Compounds and Targets
Mota Fernandes, C., Dasilva, D., Haranahalli, K., McCarthy, J. B., Mallamo, J., Ojima, I., & Del Poeta, M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01719-20 · Cited by 124
Branco, J., Miranda, I. M., & Rodrigues, A. G. (2023) · Journal of Fungi · doi:10.3390/jof9010080 · Cited by 164
Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus
Whitesell, L., Robbins, N., Huang, D. S., McLellan, C. A., Shekhar-Guturja, T., LeBlanc, E. V., Nation, C. S., Hui, R., Hutchinson, A., Collins, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08248-w · Cited by 124
Juvvadi, P. R., Lamoth, F., & Steinbach, W. J. (2014) · Fungal Biology Reviews · doi:10.1016/j.fbr.2014.02.004 · Cited by 116
“Inhibition of Hsp90 blocked fluconazole- and micafungin-induced calcineurin activation, as did calcineurin inhibition (Singh et al., 2009).”
BackgroundInfluentialLu, X., Xiao, L., Wang, L., & Ruden, D. M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.11.011 · Cited by 130
“, [65,129,130]), based on Schabel’s advice have used the yeast”
MethodDiezmann, S., Michaut, M., Shapiro, R. S., Bader, G. D., & Cowen, L. E. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002562 · Cited by 112
“Both established C. albicans client proteins that require Hsp90 for stability, Cna1 [19] and Mkc1 [18], were also low-connectivity interactors.”
BackgroundMethodInfluentialSelf-citationCurcumin Targets Cell Wall Integrity via Calcineurin-Mediated Signaling in Candida albicans
Kumar, A., Dhamgaye, S., Maurya, I. K., Singh, A., Sharma, M., & Prasad, R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01385-13 · Cited by 118
“albicans are commonly treated with either azoles or some nonazole antifungal agents, but they have pronounced side effects (2, 3).”
BackgroundBeyda, N. D., Lewis, R. E., & Garey, K. W. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r020 · Cited by 109
Echinocandins: production and applications
Emri, T., Majoros, L., Tóth, V., & Pócsi, I. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-013-4761-9 · Cited by 123
“…of data suggests that echinocandin exposure as a stress signal activates cell wall remodeling via protein kinase C (PKC), HOG, Ca 2+ -calcineurin and HSP90 pathways (Fortwendel et al. 2010; Singh et al. 2009; Singh-Babak et al. 2012; Stevens et al. 2006; Walker et al. 2008, 2012; Wiederhold 2007).”
BackgroundCalcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis
Chen, Y.-L., Brand, A., Morrison, E. L., Silao, F. G. S., Bigol, U. G., Malbas, F. F., Nett, J. E., Andes, D. R., Solis, N. V., Filler, S. G., et al. (2011) · Eukaryotic Cell · doi:10.1128/ec.00310-10 · Cited by 107
“albicans (70), indicative of a potential combination therapy.”
BackgroundFungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs
Leach, M. D., Klipp, E., Cowen, L. E., & Brown, A. J. P. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2875 · Cited by 107
Self-citationIt’s not magic – Hsp90 and its effects on genetic and epigenetic variation
Zabinsky, R. A., Mason, G. A., Queitsch, C., & Jarosz, D. F. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.05.015 · Cited by 118
Gong, Y., Li, T., Yu, C., & Sun, S. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00520 · Cited by 102
“Singh et al. revealed that impairing the calcineurin function phenocopies inhibition of Hsp90 (Singh et al., 2009), both of which result in decreased drug resistance of C. albicans to azoles.”
BackgroundInfluentialNishimoto, A. T., Sharma, C., & Rogers, P. D. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz400 · Cited by 102
Elucidating Drug Resistance in Human Fungal Pathogens
Xie, J. L., Polvi, E. J., Shekhar-Guturja, T., & Cowen, L. E. (2014) · Future Microbiology · doi:10.2217/fmb.14.18 · Cited by 100
Self-citationDual action antifungal small molecule modulates multidrug efflux and TOR signaling
Shekhar-Guturja, T., Gunaherath, G. M. K. B., Wijeratne, E. M. K., Lambert, J.-P., Averette, A. F., Lee, S. C., Kim, T., Bahn, Y.-S., Tripodi, F., Ammar, R., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2165 · Cited by 101
Self-citationEchinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management
Perlin, D. S. (2014) · Drugs · doi:10.1007/s40265-014-0286-5 · Cited by 99
“Hsp90 induces tolerance to echinocandin drugs through its principal client protein calcineurin and the downstream effector crz1 [94, 95].”
Antifungal Drug Discovery: The Process and Outcomes
Calderone, R., Sun, N., Gay-Andrieu, F., Groutas, W., Weerawarna, P., Prasad, S., Alex, D., & Li, D. (2014) · Future Microbiology · doi:10.2217/fmb.14.32 · Cited by 97
pH Signaling in Human Fungal Pathogens: a New Target for Antifungal Strategies
Cornet, M., & Gaillardin, C. (2014) · Eukaryotic Cell · doi:10.1128/ec.00313-13 · Cited by 98
Brown, A. J. P., Cowen, L. E., Pietro, A. D., & Quinn, J. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0048-2016 · Cited by 125
Self-citationResistance to Antifungal Drugs
Ben‐Ami, R., & Kontoyiannis, D. P. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.003 · Cited by 122
The fungal Achilles’ heel: targeting Hsp90 to cripple fungal pathogens
Cowen, L. E. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.03.005 · Cited by 104
Self-citationLi, P., Seneviratne, C. J., Alpi, E., Vizcaino, J. A., & Jin, L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00543-15 · Cited by 95
“HSP90 is a key regulator of cell circuitry and plays an important role in potentiating fungal resistance (50, 51).”
BackgroundGenetic and Genomic Architecture of the Evolution of Resistance to Antifungal Drug Combinations
Hill, J. A., Ammar, R., Torti, D., Nislow, C., & Cowen, L. E. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003390 · Cited by 93
“Resistance to drug combinations was assayed in 96-well microtiter plates, as previously described [16,21].”
MethodSelf-citationGenetic Drivers of Multidrug Resistance in Candida glabrata
Healey, K. R., Jimenez Ortigosa, C., Shor, E., & Perlin, D. S. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01995 · Cited by 93
“Regulators of the CWI pathway, such as Frontiers in Microbiology | www.frontiersin.org 2 December 2016 | Volume 7 | Article 1995 Hsp90 and calcineurin, can similarly influence the susceptibility of C. glabrata to echinocandin and triazole drugs (Singh et al., 2009; Miyazaki et al., 2010b).”
MethodHayes, B. M. E., Anderson, M. A., Traven, A., van der Weerden, N. L., & Bleackley, M. R. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1573-8 · Cited by 93
The Hsp90 chaperone network modulates Candida virulence traits
O’Meara, T. R., Robbins, N., & Cowen, L. E. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.05.003 · Cited by 92
“Calcineurin is required for tolerance to ergosterol biosynthesis inhibitors [70] and cell-wall inhibitors [32], and is an Hsp90 client protein in C.”
Chemosensitization as a Means to Augment Commercial Antifungal Agents
Campbell, B. C., Chan, K. L., & Jong Heon, K. I. M. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00079 · Cited by 97
The role of Candida albicans stress response pathways in antifungal tolerance and resistance
Iyer, K. R., Robbins, N., & Cowen, L. E. (2022) · iScience · doi:10.1016/j.isci.2022.103953 · Cited by 88
“…and in vivo with the pharmacological inhibitors FK506 or cyclosporin A enhances sensitivity of C. albicans to the azoles and echinocandins (Cruz et al., 2002; Sanglard et al., 2003; Singh et al., 2009), and genetic deletion of CNB1 leads to increased antifungal sensitivity (Cruz et al., 2002).”
BackgroundMethodInfluentialSelf-citationA Histone Deacetylase Complex Mediates Biofilm Dispersal and Drug Resistance in Candida albicans
Nobile, C. J., Fox, E. P., Hartooni, N., Mitchell, K. F., Hnisz, D., Andes, D. R., Kuchler, K., & Johnson, A. D. (2014) · mBio · doi:10.1128/mbio.01201-14 · Cited by 87
“Overnight cultures were grown in YPD medium at a starting cell density of ~103 per well containing 200 l of medium as previously described (33).”
MethodLu, H., Hong, T., Jiang, Y., Whiteway, M., & Zhang, S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114960 · Cited by 89
Drug resistance mechanisms and their regulation in non-albicans Candida species
Kołaczkowska, A., & Kołaczkowski, M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv445 · Cited by 87
The Hsp90 Co-Chaperone Sgt1 Governs Candida albicans Morphogenesis and Drug Resistance
Shapiro, R. S., Zaas, A. K., Betancourt-Quiroz, M., Perfect, J. R., & Cowen, L. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044734 · Cited by 86
“albicans echinocandin resistance, renders this otherwise fungistatic class of drug fungicidal, and improves echinocandin efficacy in a murine model of disseminated infection [37].”
BackgroundMethodSelf-citationDrug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis
Murphy, S. E., & Bicanic, T. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.759408 · Cited by 83
Fitness Trade-Offs Associated with the Evolution of Resistance to Antifungal Drug Combinations
Hill, J. A., O’Meara, T. R., & Cowen, L. E. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.009 · Cited by 80
Self-citationShapiro, R. S., Sellam, A., Tebbji, F., Whiteway, M., Nantel, A., & Cowen, L. E. (2012) · Current Biology · doi:10.1016/j.cub.2012.01.062 · Cited by 81
Self-citationCalcium signaling is involved in diverse cellular processes in fungi
Roy, A., Kumar, A., Baruah, D., & Tamuli, R. (2020) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2020.1785962 · Cited by 81
“In addition to calcineurin, Hsp90 has a role in providing resistance to echinocandins in C. albicans (Singh et al. 2009).”
BackgroundLamoth, F., Juvvadi, P. R., Soderblom, E. J., Moseley, M. A., Asfaw, Y. G., & Steinbach, W. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02286-13 · Cited by 74
“Fungal Hsp90 promotes resistance to azole and echinocandin drugs, which has been well demonstrated in the pathogenic yeast Candida albicans (6, 10, 11).”
BackgroundA CRISPR Interference Platform for Efficient Genetic Repression in Candida albicans
Wensing, L. F., Sharma, J., Uthayakumar, D., Proteau, Y., Chavez, A., & Shapiro, R. S. (2019) · mSphere · doi:10.1128/msphere.00002-19 · Cited by 75
Hameed, S., Dhamgaye, S., Singh, A., Goswami, S. K., & Prasad, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018684 · Cited by 69
“albicans and compromising Hsp90 phenocopies abrogated calcineurin pathway [26].”
BackgroundCombination Therapy to Treat Fungal Biofilm-Based Infections
Tits, J., Cammue, B. P. A., & Thevissen, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228873 · Cited by 69
Pfaller, M. A., Rhomberg, P. R., Messer, S. A., & Castanheira, M. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.11.008 · Cited by 67
Senn, H., Shapiro, R. S., & Cowen, L. E. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-08-0729 · Cited by 67
“The only other two Hsp90 client proteins identified to date include the protein phosphatase calcineurin and the MAP kinase Mkc1, which are key regulators of the evolution and maintenance of antifungal drug resistance (Singh et al., 2009; LaFayette et al., 2010).”
BackgroundInfluentialSelf-citationLackner, M., Tscherner, M., Schaller, M., Kuchler, K., Mair, C., Sartori, B., Istel, F., Arendrup, M. C., & Lass-Flörl, C. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00123-14 · Cited by 67
“among them are the overexpression of HSP90 (33), the overex-”
BackgroundLinking Cellular Morphogenesis with Antifungal Treatment and Susceptibility in Candida Pathogens
Sharma, J., Rosiana, S., Razzaq, I., & Shapiro, R. S. (2019) · Journal of Fungi · doi:10.3390/jof5010017 · Cited by 65
“Regulation and induction of numerous cellular stress response pathways such as the phosphatase protein calcineurin, and the molecular chaperone Hsp90 [39,123].”
BackgroundInfluentialLamoth, F., Juvvadi, P. R., Gehrke, C., Asfaw, Y. G., & Steinbach, W. J. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit530 · Cited by 62
“promoter, suggesting that Hsp90 is involved in a stress response to these drugs [5, 8].”
BackgroundEpp, E., Vanier, G., Harcus, D., Lee, A. Y., Jansen, G., Hallett, M., Sheppard, D. C., Thomas, D. Y., Munro, C. A., Mullick, A., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000753 · Cited by 61
“Additional phenotypes that calcineurin inhibition shares with ARF inhibition include synergism with azoles and echinocandins as well as reduced virulence in the bloodstream of the host [17,19,87].”
BackgroundA Call to Arms: Quest for a Cryptococcal Vaccine
Caballero Van Dyke, M. C., & Wormley, F. L. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2017.10.002 · Cited by 61
Design and Synthesis of Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors
Huang, D. S., LeBlanc, E. V., Shekhar-Guturja, T., Robbins, N., Krysan, D. J., Pizarro, J., Whitesell, L., Cowen, L. E., & Brown, L. E. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00826 · Cited by 61
Self-citationXie, J. L., Qin, L., Miao, Z., Grys, B. T., Diaz, J. D. L. C., Ting, K., Krieger, J. R., Tong, J., Tan, K., Leach, M. D., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00547-y · Cited by 60
Self-citationHistone deacetylase inhibition as an alternative strategy against invasive aspergillosis
Lamoth, F., Juvvadi, P. R., & Steinbach, W. J. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00096 · Cited by 61
“Hsp90 was shown to be essential for fungal survival and to be an important trigger of antifungal resistance to both azole and echinocandin classes and possibly to amphotericin B (Cowen and Lindquist, 2005; Cowen et al., 2009; Singh et al., 2009; Lamoth et al., 2012, 2014b; Blum et al., 2013).”
BackgroundTunicamycin Potentiates Antifungal Drug Tolerance via Aneuploidy in Candida albicans
Yang, F., Gritsenko, V., Slor Futterman, Y., Gao, L., Zhen, C., Lu, H., Jiang, Y.-Y., & Berman, J. (2021) · mBio · doi:10.1128/mbio.02272-21 · Cited by 59
“The calcineurin pathway is also required for tolerance to echinocandins (30).”
BackgroundChatterjee, S., & Tatu, U. (2017) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0005836 · Cited by 57
Heat shock protein 90 (Hsp90): A novel antifungal target against Aspergillus fumigatus
Lamoth, F., Juvvadi, P. R., & Steinbach, W. J. (2016) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2014.947239 · Cited by 57
“A similar increase of susceptibility to the echinocandins was observed (Singh et al., 2009).”
BackgroundCaplan, T., Polvi, E. J., Xie, J. L., Buckhalter, S., Leach, M. D., Robbins, N., & Cowen, L. E. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.084 · Cited by 56
Self-citation
Metadata
- Authors
- Singh, S. D., Robbins, N., Zaas, A. K., Schell, W. A., Perfect, J. R., & Cowen, L. E.
- Affiliations
- University of Toronto (CA)
- Duke Medical Center (US)
- Corresponding author
- Cowen, Leah E.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-07-31
- Volume
- 5
- Issue
- 7
- Pages
- e1000532
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC2712069
- OpenAlex
- W2087273774
- Cited by
- 362
- References
- 60
- Citations by year
- 2026: 19 · 2025: 26 · 2024: 14 · 2023: 25 · 2022: 24 · 2021: 28 · 2020: 23 · 2019: 18 · 2018: 18 · 2017: 18 · 2016: 20 · 2015: 16 · 2014: 32 · 2013: 25 · 2012: 23
- FWCI
- 12.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Burroughs Wellcome Fund
- University of Toronto
- National Institutes of Health
- Canadian Institutes of Health Research (MOP-86452)
- Natural Sciences and Engineering Research Council of Canada
- National Institute of Allergy and Infectious Diseases (AI 73896, R56AI028388, AI28388, R01AI073896, R01AI028388, K08AI065837)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- HSP90, calcineurin, Candida albicans, echinocandin resistance, antifungal resistance, candidiasis, Hsp90 client proteins, Crz1, calcineurin signaling, molecular chaperones, fungal cell wall biosynthesis, HSP90 inhibition, combination antifungal therapy, systemic candidiasis
- MeSH terms
- Micafungin, Analysis of Variance, Animals, Antifungal Agents, Azoles, Candida albicans, Candidiasis, Disease Models, Animal, DNA-Binding Proteins, Fungal Proteins, Male, Stress, Physiological, Transcription Factors, HSP90 Heat-Shock Proteins, Calcineurin, Drug Resistance, Fungal, Mice, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.